Core Viewpoint - The company is actively monitoring the development of 6G communication technology, which is currently in the research and exploration phase, and is assessing potential collaboration and application opportunities in the future [1] Group 1: Company Position - The company has stated that its RF-related products have not yet been applied in the practical scenarios of 6G technology [1] - The company plans to leverage its technological accumulation and business layout to evaluate potential collaborations and applications in the 6G field [1] Group 2: Industry Context - 6G communication technology is still in the frontier technology reserve and research exploration stage, indicating that the industry is in the early phases of development [1] - The company is closely tracking technological developments, application trends, and market opportunities within the 6G sector [1]

Core Viewpoint - The company is actively monitoring the development of 6G communication technology, which is currently in the research and exploration phase, and is assessing potential applications and market opportunities [1] Group 1: Company Position - The company has not yet applied its radio frequency products to any practical scenarios related to 6G technology [1] - The company plans to leverage its technological expertise and business layout to explore potential collaborations and applications in the 6G field [1] Group 2: Industry Context - 6G communication technology is still in the early stages of technological reserve and research exploration [1] - The company is committed to closely tracking trends and developments in the 6G technology landscape [1]

Core Insights - Weisi Medical achieved a revenue of 326 million yuan in the first three quarters of 2025, representing a year-on-year growth of 11.58% [1] - The net profit attributable to shareholders reached 102 million yuan, with a year-on-year increase of 30.68% [1] - Operating cash flow net amount was 104 million yuan, showing a significant year-on-year growth of 69.02% [1] Quarterly Performance - In Q3 2025, Weisi Medical reported a revenue of 115 million yuan, reflecting a year-on-year growth of 14.87% [1] - The net profit attributable to shareholders for the quarter was 32.82 million yuan, with a year-on-year increase of 14.99% [1] - The operating cash flow net amount for Q3 was 39.62 million yuan, marking a year-on-year growth of 33.74% [1] Company Strategy and Technology - Weisi Medical is recognized as a national-level "specialized and innovative" small giant enterprise, leveraging six core technology platforms: magnetic stimulation, electrical stimulation, electrophysiology, robotics, laser, and radiofrequency [1] - The company focuses on three strategic areas: brain-computer interfaces, rehabilitation robots, and AI healthcare, aiming to create a new rehabilitation medical system that is precise, intelligent, and closed-loop [1] - Weisi Medical is committed to driving technological upgrades in the industry and transforming clinical paradigms through a comprehensive "diagnosis-treatment-rehabilitation" cycle [1] International Expansion - The company is accelerating its internationalization efforts by actively participating in international exhibitions and receiving positive market feedback [2] - With ongoing breakthroughs in product qualification for overseas markets, international business is expected to become a new growth engine for the company's performance in the medium to long term [2]